Through this collaboration, the companies will jointly develop and commercialize MK-6070 worldwide, except in Japan, where Merck will retain exclusivity.
Daiichi Sankyo and Merck Expand Collaboration to Develop Delta-Like Ligand MK-6070 Targeting T Cell Attractant
Leave a Comment
